Pritesh Shah
Equibles does not estimate personal net worth.
About Pritesh Shah
NovoCure Ltd reported in an 8-K filed January 4, 2024 that Pritesh Shah resigned as Chief Growth Officer, effective January 1, 2024. The proxy statement of NovoCure Ltd reports total compensation of $5,180,138 for Pritesh Shah in fiscal 2023, including a base salary of $500,000. Disclosed compensation is on record for 6 fiscal years.
“Effective January 1, 2024, Pritesh Shah, Chief Growth Officer of the Company, resigned his position as an executive officer of the Company and agreed to become a Senior Advisor to the Chief Executive Officer, a non-executive position.”
Affiliation history
-
NovoCure Ltd (NVCR)
Proxy statement
Start not stated–2024-01-01
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | NovoCure Ltd (NVCR) | Chief Commercial Officer | $500,000 | $5,180,138 |
| 2022 | NovoCure Ltd (NVCR) | Chief Commercial Officer | $500,000 | $6,316,633 |
| 2021 | NovoCure Ltd (NVCR) | Chief Commercial Officer | $500,000 | $5,506,894 |
| 2020 | NovoCure Ltd (NVCR) | Chief Commercial Officer | $481,250 | $5,940,598 |
| 2019 | NovoCure Ltd (NVCR) | Chief Commercial Officer | $425,000 | $3,673,933 |
| 2018 | NovoCure Ltd (NVCR) | Chief Commercial Officer | $400,000 | $3,070,496 |